Breaking Down Catalyst Biosciences, Inc. (CBIO) Financial Health: Key Insights for Investors

Curious whether Catalyst Biosciences (CBIO) is a buy, hold or a watchlist candidate? Trading at $13.21 (down -$0.89 / -0.06%) as of Tuesday, December 16, 09:51:25 UTC, the company posted Q3 2025 total revenues of $148.4M (up 15.3% year-over-year) with product revenue matching that figure and a trailing 12-month revenue of $578.2M (net profit margin 37.6%); Q3 operating income landed at $66.3M while GAAP net income was $52.8M ($0.43/share) and non-GAAP net income $86.1M ($0.70/share), yet valuation multiples remain rich - P/E of 94, P/B of 10.60 and EV/EBITDA of 57.11 - even as cash and equivalents stood at $689.9M (Sept. 30, 2025) and debt-to-equity sat at -0.43; with market cap near $694.30M (March 2025), a year-to-date return of -36.45% versus the S&P 500's +12.22%, and quarter-end net sales of $22M with $4M net profit (March 2025), read on for a data-driven breakdown of the financials, valuation, risks and growth vectors that investors need to weigh.

Catalyst Biosciences, Inc. (CBIO) - Revenue Analysis

• Equity listing: USA market (Ticker: CBIO)
• Latest trade price: 13.21 USD
• Price change: -0.89 USD (-0.06%) vs. previous close
• Latest trade time (UTC): Tuesday, December 16, 09:51:25

Revenue dynamics for Catalyst Biosciences, Inc. (CBIO) should be interpreted against its current market data above and its biotech stage profile. Key revenue-related considerations:

• Revenue base: Historically limited for early-stage biotechs - licensing, milestone, and collaboration receipts drive episodic revenue rather than steady product sales.
• Near-term drivers: Potential milestone payments from partnerships and progress in pipeline assets (clinical-stage catalysts) that may trigger one-time revenue events.
• Burn vs. revenue: Cash burn typically exceeds operating revenue in development-stage biotech firms; investors must weigh cash runway against possible upcoming milestones.
• Valuation sensitivity: With a latest price of 13.21 USD, market capitalization and per-share valuations will be highly sensitive to announcements of clinical progress or partnership milestones.

• Investor action points:
  • Monitor corporate disclosures for milestone receipts, collaboration agreements, and cash-balance updates.
  • Track clinical timelines closely - positive readouts often precede licensing/royalty discussions.
  • Compare implied market valuation at 13.21 USD against peer-stage biotech multiples and recent transactions.

Further company context, including strategic priorities and long-term positioning, is available here: Mission Statement, Vision, & Core Values (2026) of Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc. (CBIO) - Profitability Metrics

• Total revenues Q3 2025: $148.4 million (up 15.3% vs Q3 2024 $128.7M).
• Product revenue, net, Q3 2025: $148.4 million (up 17.4% vs Q3 2024 $126.4M).
• Net sales for quarter ending March 2025: $22 million; net profit: $4 million.
• Trailing 12-month revenue (as of Dec 11, 2025): $578.2 million with a 37.6% net profit margin.
• Market capitalization (approx., March 2025): $694.30 million.
• Year-to-date return as of September 2025: -36.45% (vs S&P 500 YTD +12.22%).

• Margin dynamics: a 37.6% net profit margin on $578.2M TTM revenue implies net income ≈ $217.4M for the trailing 12 months.
• Quarter-level profitability: Q1 (Mar) net sales of $22M produced a $4M net profit (net margin ~18.2% for that quarter), indicating variability quarter-to-quarter versus TTM performance.
• Growth vs scale: Product revenues showed mid-teens YoY growth in Q3 2025 while TTM revenue positions the company at meaningful scale, supporting operating leverage if cost structure remains disciplined.
• Equity performance risk: Despite fundamental revenue and margin strength, the stock's YTD -36.45% through Sep 2025 signals market concerns or broader sector/market pressures relative to S&P 500 gains.

Catalyst Biosciences, Inc. (CBIO) - Debt vs. Equity Structure

• Profitability trajectory: Operating income rose 30.2% YoY, and both GAAP and non‑GAAP net income increased - non‑GAAP up ~$15.0M YoY.
• Per‑share gains: GAAP EPS $0.43 vs $0.37; non‑GAAP EPS $0.70 vs $0.60, supporting improved shareholder earnings.
• Valuation premium: P/E 94 and P/B 10.60 indicate investors are pricing significant future growth or scarcity value into the equity.
• Market sensitivity: EV/EBITDA 57.11 suggests a thin margin for error-earnings misses could lead to sharp valuation re‑ratings.

• Equity‑driven valuation: The elevated P/E and P/B point to an equity‑heavy market capitalization narrative-investors are assigning high value to future earnings and intangibles rather than current book capital.
• Leverage interpretation: A very high EV/EBITDA typically reflects a market that prices future growth into enterprise value; absent large reported debt reductions or material cash reserves disclosed in the period, this implies reliance on equity valuation rather than leverage for capital support.
• Risk profile: With premium equity pricing, Catalyst Biosciences' capital structure appears sensitive to operational performance-sustained profit growth supports the high multiples, while setbacks would pressure the equity more than a more debt‑balanced firm.

Catalyst Biosciences, Inc. (CBIO) - Liquidity and Solvency

• Debt-to-Equity Ratio: -0.43 (March 2025) - indicates negative shareholders' equity (debt exceeds reported book equity).
• Market Capitalization: ~$694.30 million (March 2025).
• Quarter (ending March 2025): Net sales $22.0M; Net profit $4.0M.
• Trailing 12-month revenue: $578.2M (as of Dec 11, 2025) with a 37.6% net profit margin.
• Valuation metrics: P/E ratio 94 and Price/Book 10.60 (both as of June 17, 2025) - signaling a high premium relative to earnings and book value.

• Negative debt-to-equity suggests balance-sheet leverage or accumulated losses; monitor book equity trends and any potential recapitalization.
• Strong trailing revenue and high net margin indicate operational profitability, but high P/E and P/B reflect elevated market expectations.
• Quarterly profitability (Q1 2025: $4M profit on $22M sales) supports cash-generation potential; reconcile with liquidity (cash, short-term liabilities) when available.

Catalyst Biosciences, Inc. (CBIO) Valuation Analysis

• Cash and cash equivalents: $689.9 million (as of September 30, 2025)
• Market capitalization: approximately $694.30 million (March 2025)
• Net sales (quarter ending March 2025): $22 million; Net profit: $4 million

• High cash balance vs. market cap: Cash (~$689.9M) is roughly equal to market cap (~$694.3M), indicating strong liquidity relative to valuation.
• Elevated valuation multiples: P/E of 94 and EV/EBITDA of 57.11 signal premium pricing relative to earnings; P/B of 10.60 indicates investors pay well above book value.
• Quarterly profitability: $4M net profit on $22M sales yields a net margin ~18.2%, supporting positive earnings but still small absolute profit versus market valuation.

Catalyst Biosciences, Inc. (CBIO) - Risk Factors

• P/E ratio: 94 (as of June 17, 2025)
• Price to Book Value (P/B): 10.60 (as of June 17, 2025)
• EV/EBITDA: 57.11 (as of June 17, 2025)
• Market capitalization: ~$694.30 million (as of March 2025)

• Quarter ending March 2025 - Net sales: $22 million; Net profit: $4 million
• Trailing 12-month revenue (as of December 11, 2025): $578.2 million
• Trailing 12-month net profit margin: 37.6%

• High P/E (94) implies expectations of strong future earnings growth; current earnings are modest relative to market price.
• P/B of 10.60 indicates investors are paying a large premium over book equity-intangible value or growth prospects priced in.
• EV/EBITDA of 57.11 suggests the enterprise value is high relative to EBITDA, signaling limited margin for valuation error if growth slows.
• Robust TTM revenue ($578.2M) and a 37.6% net profit margin show solid recent profitability, which can justify premium multiples if sustainable.

• Valuation sensitivity: With elevated multiples (P/E, P/B, EV/EBITDA), share price is vulnerable to disappointments in revenue growth, margin pressure, or regulatory setbacks.
• Execution risk: Sustaining a 37.6% net margin and converting pipeline expectations into repeatable revenue presents operational and commercial execution challenges.
• Market-cap and liquidity: A market cap near $694.3M narrows margin for error versus larger peers; volatility can amplify on mixed news.
• Concentration and scalability: Quarterly sales of $22M and net profit of $4M (Mar 2025) highlight current scale; reliance on product launches or a small set of revenue drivers increases business concentration risk.
• Macro and sector risk: Biotech valuations are cyclical; higher rates, tighter credit, or risk-off flows can compress premium multiples rapidly.
• Comparative valuation: Premium P/B and EV/EBITDA may make the stock less attractive versus peers unless growth and margins continue to outpace the industry.

Catalyst Biosciences, Inc. (CBIO) - Growth Opportunities

• Quarter ended March 2025: Net sales $22.0M; Net profit $4.0M.
• Trailing 12-month revenue (as of Dec 11, 2025): $578.2M with a 37.6% net profit margin.
• Market capitalization: ≈ $694.30M (March 2025).

• High valuation multiples: P/E of 94 and EV/EBITDA of 57.11 imply investor expectations for strong future growth - increases downside risk if execution falters.
• Premium to book: P/B of 10.60 signals market pricing well above accounting equity; limited margin for valuation compression.
• Concentration and execution risk: Rapid revenue scale (TTM $578.2M) requires sustaining commercial execution, supply chain stability, and favorable reimbursement dynamics.
• Profitability sensitivity: While current margins are robust (37.6%), margins can be volatile in biotech due to R&D spend, pricing pressure, or competitive dynamics.
• Market-cap liquidity and volatility: ~ $694.3M market cap can result in larger price swings on news, partnerships, or trial outcomes.
• Macroeconomic and sector risk: Rising rates or sector de-risking can disproportionately affect high-multiple healthcare names.

• Valuation vs. fundamentals: Compare growth runway (product launches, label expansions, partnerships) to current multiples - the company needs continued topline expansion and margin preservation to justify pricing.
• Profit conversion: Current quarterly net profit and strong TTM margin are positive signals, but investors should monitor free cash flow, R&D cadence, and capital allocation.
• Event-driven risk: Clinical, regulatory, or commercial milestones will likely drive significant share-price movement given current valuation sensitivity.